References: Hair growth and hair loss
Cancer. 1975 Jul;36(1):90-7.
Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
Jones SE, Durie BG, Salmon SE.
Fifty-five consecutive women with advanced breast cancer were treated with a combination of adriamycin (40 mg/m2 administered intravenously on day 1) and cyclophosphamide (200 mg/m2/day given orally in divided doses for 4 days on days 3-6). Courses were repeated at 21-28-day intervals. The mean age for the 55 patients was 55 years (range, 37-77 years); 20% of the patients were 65 years or older. All patients were evaluable. Objective response (at least a 50% decrease in the size of all measurable lesions lasting for at least 1 month) was noted in 40 (80%) of the 50 patients who received an adequate trial of chemotherapy (a minimum of two courses). Six of the 40 responses observed were complete. The median duration of response was 10 months. Actuarial survival for the entire group of 55 patients was 80% at 6 months after initiating chemotherapy and 70% at 12 months. Survival for the 40 responding patients was 95% at 6 months and 80% at 12 months. Response rates by site of involvement were: soft tissue, 20/25 (80%); lymph node, 15/19 (79%); bone, 21/25 (84%); lung, 15/18 (83%); pleural effusion, 6/8 (75%); and liver, 7/10 (70%). Eighty-three percent of the responses were apparent after two courses of treatment and 98% were apparent after four courses. Toxicity was acceptable and included nausea, myelosuppression, alopecia, and reversible congestive heart failure (in 2 patients who received 550 mg/m2 of adriamycin). Chemotherapy with adriamycin and cyclophosphamide proved to be safe and effective for out-patient treatment of advanced breast cancer.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1203853&dopt=Abstract
Oncologist. 1998;3(3):155-164.
UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer.
Hoff PM, Pazdur R.
Division of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA.
UFT is an oral antineoplastic agent that combines the 5-fluorouracil (5-FU) prodrug tegafur with uracil in a 1:4 molar ratio. Uracil is added because it competitively inhibits the degradation of 5-FU, resulting in increased plasma and tumor 5-FU concentrations. Although UFT has been available in Japan since 1984, it has only recently been in clinical development in the United States. Beginning in 1991, phase I/II trials of UFT have been conducted in the United States to establish a maximum tolerated dose, evaluate its pharmacokinetics, and assess its efficacy and safety in advanced colorectal cancer. Pharmacokinetic studies demonstrated that UFT 300 mg/m²/day administered in divided doses every 8 h for 28 days provides an effective oral method of delivering a prolonged exposure to 5-FU. UFT plus oral leucovorin is well tolerated, with diarrhea as the dose-limiting toxicity. Unlike i.v. administered 5-FU, UFT is not associated with significant myelosuppression, mucositis, hand-foot syndrome, or alopecia, and patients have a decreased risk of toxicity-related hospitalization. In a phase II trial in advanced colorectal cancer, UFT plus oral leucovorin produced an objective response rate of 42%, with survival similar to weekly i.v. 5-FU plus leucovorin. The reduced toxicity, efficacy comparable to i.v. 5-FU, and the convenience and cost savings of an orally administered regimen have potential pharmacoeconomic advantages.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10388099&dopt=Abstract [PubMed - as supplied by publisher]
Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):549-53.
Androgenetic alopecia and prostate cancer: findings from an Australian case-control study.
Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, Boyle P, Hopper JL.
Cancer Epidemiology Centre, Anti-Cancer Council of Victoria, Melbourne, VIC 3053 Australia.
The purpose of this study was to examine the relationship between androgenetic alopecia (AA) and prostate cancer with particular emphasis on early age at diagnosis and higher grade tumors. We conducted an age-stratified, population-based case-control study in Australia of men who were diagnosed before 70 years of age during 1994-1997 with histopathology-confirmed adenocarcinoma of the prostate, excluding well-differentiated tumors. Controls were selected from the electoral rolls, and the frequency was matched on age. After excluding subjects with missing values, the analysis was based on 1446 cases and 1390 controls of whom direct observations were made of their pattern of AA during face-to-face interviews. Our data suggest an association between prostate cancer and vertex baldness; compared with men who had no balding, the adjusted odds ratio (OR) was 1.54 (1.19-2.00). No associations were found between prostate cancer and frontal baldness or when frontal baldness was present concurrently with vertex baldness. The ORs were 0.98 (0.79-1.23) and 1.14 (0.90-1.45), respectively. The highest ORs were for high-grade disease in men 60-69 years of age: 1.80 (1.02-3.16) for frontal baldness; 2.91 (1.59-5.32) for vertex baldness; and 1.95 (1.10-3.45) for frontal and vertex baldness. This association between the pattern of AA and prostate cancer points to shared androgen pathways that are worthy of additional investigation.
online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12050096&dopt=Abstract
Natural Herbal Supplements ||
Hair Million herbal formula for hair loss and hair growth ||
Hair growth research references ||
Online Pharmacy : discount prescription medication ||